EUVIMEDEUVIMED entdecken
Crossref

A Single-cell Atlas Identifies Pretreatment Features of Primary Imatinib Resistance in Chronic Myeloid Leukemia

Vaidehi Krishnan iD, Florian Schmidt, Zahid Nawaz iD, Prasanna Nori Venkatesh iD, Kian Leong Lee iD, Xi Ren, Zhu En Chan, Mengge Yu iD, Meera Makheja, Nirmala Arul Rayan, Michelle Gek Liang Lim, Alice Man Sze Cheung iD und 10 weitere

Blood · 01.03.2023

DOI: 10.1182/blood.2022017295 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, online erschienen am 01.03.2023. Verfasst von Vaidehi Krishnan und 21 weiteren Autor:innen. Beteiligte Einrichtung: Cancer & Stem Cell Biology Signature Research Programme, Duke-NUS Medical School, Singapore. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Die Arbeit wurde bisher 28-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary resistance to tyrosine kinase inhibitors (TKI) is a significant barrier to optimal outcomes in chronic myeloid leukemia, but little is known about the factors contributing to response heterogeneity. Using scRNA-sequencing, we identified eight statistically significant features in pretreatment bone marrow mononuclear cells which correlated with either sensitivity (major molecular response or MMR) or extreme resistance to imatinib (eventual blast crisis transformation). Employing machine-learning, we also identified LSC and NK gene expression profiles predicting imatinib response with >80% accuracy, including zero false positives for predicting BC. A canonical erythroid-specifying (TAL1/KLF1/GATA1) regulon was a hallmark of LSCs from patients with MMR and was associated with erythroid progenitor (ERP) expansion in vivo (p<0.05), and a marked 2-10-fold (6.3-fold in Group A vs 1.09-fold in Group C) erythroid over myeloid bias in vitro. Notably, ERPs demonstrated exquisite TKI sensitivity compared to myeloid progenitors (p<0.001). These LSC features were lost with progressive resistance, and in patients who transformed, MYC- and IRF1-driven inflammatory regulons became evident. Patients with MMR also exhibited a 56-fold expansion (p<0.01) of a normally rare subset of hyperfunctional adaptive-like NK cells (CD57+NKG2C+) which diminished with progressive resistance, while patients destined for BC accumulated inhibitory NKG2A+ NK cells favoring NK cell tolerance (through HLA-E binding on target cells). Finally, we developed a parsimonious set of antibodies to validate our scRNA-seq findings. This panel will be useful in prospective studies of primary resistance, and assessing the contribution of predetermined versus acquired factors in TKI response heterogeneity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveHumansImatinib MesylateProspective StudiesBlast CrisisDrug Resistance, Neoplasm

Substanzen

Imatinib MesylateProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Cancer & Stem Cell Biology Signature Research Programme, Duke-NUS Medical School, Singapore.
  • Laboratory of Systems Biology and Data Analytics, Genome Institute of Singapore, Singapore.
  • Department of Haematology, Singapore General Hospital, Singapore.
  • Division of Medical Sciences, National Cancer Centre, Singapore.
  • Advanced Cell Therapy and Research Institute, Singapore.
  • Oncology Academic Clinical Program, Duke-NUS Medical School, Singapore.

ORCID-Profile: Vaidehi Krishnan, Zahid Nawaz, Prasanna Nori Venkatesh, Kian Leong Lee, Mengge Yu, Alice Man Sze Cheung, Hein Than, Tuan Zea Tan, William Ying Khee Hwang, S Tiong Ong

Zitieren

APA

Krishnan, V., Schmidt, F., Nawaz, Z., Venkatesh, P. N., Lee, K. L., Ren, X., Chan, Z. E., Yu, M., Makheja, M., Rayan, N. A., Lim, M. G. L., Cheung, A. M. S., Bari, S., Chng, W. J., Than, H., Ouyang, J., Rackham, O., Tan, T. Z., Hwang, W. Y. K., …, & Ong, S. T. (2023). A Single-cell Atlas Identifies Pretreatment Features of Primary Imatinib Resistance in Chronic Myeloid Leukemia. Blood. https://doi.org/10.1182/blood.2022017295

Vancouver

Krishnan V, Schmidt F, Nawaz Z, Venkatesh PN, Lee KL, Ren X, et al. A Single-cell Atlas Identifies Pretreatment Features of Primary Imatinib Resistance in Chronic Myeloid Leukemia. Blood. 2023. doi:10.1182/blood.2022017295

BibTeX
@article{Krishnan2023,
  author = {Krishnan, Vaidehi and Schmidt, Florian and Nawaz, Zahid and Venkatesh, Prasanna Nori and Lee, Kian Leong and Ren, Xi and Chan, Zhu En and Yu, Mengge and Makheja, Meera and Rayan, Nirmala Arul and Lim, Michelle Gek Liang and Cheung, Alice Man Sze and Bari, Sudipto and Chng, Wee Joo and Than, Hein and Ouyang, John and Rackham, Owen and Tan, Tuan Zea and Hwang, William Ying Khee and Chuah, Charles and Prabhakar, Shyam and Ong, S Tiong},
  title = {A Single-cell Atlas Identifies Pretreatment Features of Primary Imatinib Resistance in Chronic Myeloid Leukemia},
  journal = {Blood},
  year = {2023},
  doi = {10.1182/blood.2022017295}
}
Kostenlos starten →